Visp: Lonza invests 400 million
The chemical and pharmaceutical company Lonza plans to invest CHF 400 million in its Biopark in Visp (VS).

In July 2017, Lonza had started building "Ibex Dedicate", a modular, technology-independent biomanufacturing concept for third parties. Now, the 100,000 sqm biopark is to be expanded with two further offerings: "Ibex Design" and "Ibex Develop".
Both facility concepts offer a wide range of manufacturing options from early development to full commercialization, Lonza says. Customers will be able to lease in and handle the entire product management cycle in one place in the future. The new facilities and offerings are expected to be available from 2020. (ah)
(Visited 113 times, 1 visits today)